{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T09:49:39Z","timestamp":1772531379063,"version":"3.50.1"},"reference-count":47,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["No. SZXK015"],"award-info":[{"award-number":["No. SZXK015"]}]},{"name":"Guangdong Provincial and National Key Clinical Specialty Construction Project and National Key Clinical Specialty Construction Project"},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["No. SZSM202411026"],"award-info":[{"award-number":["No. SZSM202411026"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Most studies on breast cancer susceptibility gene (BRCA) mutations have focused on Caucasian populations in Europe and North America. Currently, there is a lack of literature and data research in related fields in Shenzhen, China, and even in Guangdong Province. This study aims to establish a registry of BRCA mutation carriers by analyzing and comparing the pathological features of breast cancer patients carrying and not carrying BRCA mutations in the Shenzhen area.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Blood samples were collected from 406 breast cancer patients who met the inclusion criteria (from July 2016 to November 2024) and genetic testing was performed using next-generation sequencing (NGS) technology. Patients were divided into two groups: BRCA mutation group with 54 cases and BRCA non-mutation group with 352 cases. A retrospective analysis was conducted on patient data collected from the health information system of Shenzhen People\u2019s Hospital, including demographic data, clinical pathological characteristics, and variables related to molecular typing. We used SPSS software for statistical analysis of the data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In 406 breast cancer patients, the average age of the BRCA mutation group was 39.3\u00a0\u00b1\u00a09.2 years, while the average age of the BRCA non-mutation group was 41.8\u00a0\u00b1\u00a08.8 years. The proportion of tumors \u2264 2 cm in the mutation group is 72.2%, higher than the 53.1% in the non-mutation group (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.009, 95% confidence interval [1.220\u20134.313]). The proportion of grade III pathologic grading in the mutation group is 59.3%, higher than the 36.1% in the non-mutation group (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.001, 95% confidence interval [1.436\u20134.625]). In the mutation group, there are seven cases of Luminal A (13.0%), zero cases of Luminal B (Her-2 positive) (0%), and 23 cases of triple-negative breast cancer (TNBC) (42.6%). In the non-mutation group, there are 93 cases of Luminal A (26.4%), 54 cases of Luminal B (Her-2 positive) (15.3%), and 67 cases of TNBC (19.0%). (Luminal A:\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.033, 95% confidence interval [0.181\u20130.950]; Luminal B (Her-2 positive):\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.002; TNBC:\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001, 95% confidence interval [1.730\u20135.759]). The expression levels of estrogen receptor (ER) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.009), progesterone receptor (PR) (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001), and Ki-67 (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001) show significant differences between the BRCA mutation group and the BRCA non-mutation group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to BRCA non-mutated patients, BRCA mutated patients in Shenzhen have smaller tumor volumes, with pathological grades mainly at grade 3, and molecular subtypes predominantly being triple-negative breast cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20813","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:20:24Z","timestamp":1772526024000},"page":"e20813","source":"Crossref","is-referenced-by-count":0,"title":["Pathological features of BRCA-mutated breast cancer in Shenzhen, China: a single-center study"],"prefix":"10.7717","volume":"14","author":[{"given":"Jiayu","family":"Guan","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University, Shenzhen People\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihang","family":"Lin","sequence":"additional","affiliation":[{"name":"Guangxi Medical University Cancer Hospital, Key Laboratory of Breast Cancer Diagnosis and Treatment Research of Guangxi Department of Education, Nanning, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjia","family":"Liu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University, Shenzhen People\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Zhou","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University, Shenzhen People\u2019s Hospital, Shenzhen, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4443","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"10.7717\/peerj.20813\/ref-1","doi-asserted-by":"publisher","first-page":"103714","DOI":"10.1016\/j.esmoop.2024.103714","article-title":"Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology","volume":"9","author":"Agostinetto","year":"2024","journal-title":"ESMO Open"},{"key":"10.7717\/peerj.20813\/ref-2","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/jco.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20813\/ref-3","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","article-title":"BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing","volume":"131","author":"Arun","year":"2024","journal-title":"British Journal of Cancer"},{"key":"10.7717\/peerj.20813\/ref-4","doi-asserted-by":"publisher","first-page":"102796","DOI":"10.1016\/j.jogoh.2024.102796","article-title":"Prognostic value of BRCA1 promoter methylation for patients with epithelial ovarian cancer","volume":"53","author":"Aza\u00efs","year":"2024","journal-title":"Journal of Gynecology Obstetrics and Human Reproduction"},{"key":"10.7717\/peerj.20813\/ref-5","doi-asserted-by":"publisher","first-page":"3000605231223426","DOI":"10.1177\/03000605231223426","article-title":"BRCA mutation status and pathological characterization of breast cancer in Zhoushan Islands, China","volume":"52","author":"Bao","year":"2024","journal-title":"Journal of International Medical Research"},{"key":"10.7717\/peerj.20813\/ref-6","doi-asserted-by":"publisher","first-page":"e1180","DOI":"10.1002\/cnr2.1180","article-title":"Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau","volume":"2","author":"Cao","year":"2019","journal-title":"Cancer Reports"},{"key":"10.7717\/peerj.20813\/ref-7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13053-022-00242-0","article-title":"Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis","volume":"20","author":"Caramelo","year":"2022","journal-title":"Hereditary Cancer in Clinical Practice"},{"key":"10.7717\/peerj.20813\/ref-8","article-title":"Analysis of the characteristics of BRCA1\/2 mutations and the clinicopathologic features of familial breast cancer in Hebei Province","author":"Chen","year":"2007","journal-title":"Master\u2019s degree"},{"key":"10.7717\/peerj.20813\/ref-9","article-title":"The clinicopathologic characteristic and BRCA1\/2 mutation in familial breast cancer","author":"Chen","year":"2019","journal-title":"Master\u2019s degree"},{"key":"10.7717\/peerj.20813\/ref-10","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.12354\/j.issn.1000-8179.2022.20221002","article-title":"Comparison of clinicopathological characteristics between BRCA1 and BRCA2 mutation carriers among Chinese women with breast cancer","volume":"49","author":"Chen","year":"2022","journal-title":"Chinese Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20813\/ref-11","doi-asserted-by":"publisher","first-page":"954","DOI":"10.19401\/j.cnki.1007-3639.2021.10.013","article-title":"China Anti-Cancer Association Guidelines and norms for diagnosis and treatment of breast cancer (2021 Edition)","volume":"31","author":"Chinese Anti-Cancer Association\u00a0CoBCS","year":"2021","journal-title":"China Oncology"},{"key":"10.7717\/peerj.20813\/ref-12","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1148\/rg.2020190084","article-title":"BRCA and beyond: comprehensive image-rich review of hereditary breast and gynecologic cancer syndromes","volume":"40","author":"Chung","year":"2020","journal-title":"Radiographics"},{"key":"10.7717\/peerj.20813\/ref-13","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11912-023-01488-0","article-title":"PARP inhibitors in breast cancer: a short communication","volume":"26","author":"Daly","year":"2024","journal-title":"Current Oncology Reports"},{"key":"10.7717\/peerj.20813\/ref-14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial high-risk assessment: breast, ovarian, and pancreatic, Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Daly","year":"2021","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10.7717\/peerj.20813\/ref-15","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.gore.2022.100989","article-title":"Perceptions and care recommendations from previvors: qualitative analysis of female BRCA1\/2 mutation Carriers\u2019 experience with genetic testing and counseling","volume":"41","author":"Dibble","year":"2022","journal-title":"Gynecologic Oncology Reports"},{"key":"10.7717\/peerj.20813\/ref-16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41436-019-0740-6","article-title":"Systematic misclassification of missense variants in BRCA1 and BRCA2 \u201ccoldspots\u201d","volume":"22","author":"Dines","year":"2020","journal-title":"Genet Med"},{"key":"10.7717\/peerj.20813\/ref-17","article-title":"Characterization of mutations in BRCA1\/2 and the relationship with clinic-pathological features of breast cancer in a hereditarily high-risk sample of Chinese population","author":"Fang","year":"2018","journal-title":"Master\u2019s degree"},{"key":"10.7717\/peerj.20813\/ref-18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41523-024-00667-x","article-title":"Susceptibility gene mutations in germline and tumors of patients with HER2-negative advanced breast cancer","volume":"10","author":"Fasching","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"10.7717\/peerj.20813\/ref-19","doi-asserted-by":"publisher","first-page":"2472432","DOI":"10.1080\/15384047.2025.2472432","article-title":"The search for a TNBC vaccine: the guardian vaccine","volume":"26","author":"Fines","year":"2025","journal-title":"Cancer Biology and Therapy"},{"key":"10.7717\/peerj.20813\/ref-20","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-6834151\/v1","article-title":"Research on the pathological features of BRCA-mutated breast cancer in Shenzhen, China: a single-center study","author":"Guan","year":"2025","journal-title":"Research Square"},{"key":"10.7717\/peerj.20813\/ref-21","doi-asserted-by":"publisher","first-page":"302","DOI":"10.14744\/nci.2023.93196","article-title":"General analysis of breast cancer patients tested for BRCA mutations and evaluation of acute radiotherapy toxicity","volume":"11","author":"Gul","year":"2024","journal-title":"Northern Clinics of \u0130stanbul"},{"issue":"3","key":"10.7717\/peerj.20813\/ref-22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/diagnostics13030470","article-title":"Clinical evidence of circulating tumor DNA application in aggressive breast cancer","volume":"13","author":"Hejjioui","year":"2023","journal-title":"Diagnostics"},{"issue":"7","key":"10.7717\/peerj.20813\/ref-23","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.3390\/ijms23073754","article-title":"BRCA1\/2 Serves as a Biomarker for Poor Prognosis in Breast Carcinoma","volume":"23","author":"Jin","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"issue":"10","key":"10.7717\/peerj.20813\/ref-24","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/medicina56100514","article-title":"Germline BRCA mutation and clinical outcomes in breast cancer patients focusing on survival and failure patterns: a long-term follow-up study of Koreans","volume":"56","author":"Kim","year":"2020","journal-title":"Medicina"},{"key":"10.7717\/peerj.20813\/ref-25","doi-asserted-by":"publisher","first-page":"1002360","DOI":"10.3389\/fonc.2022.1002360","article-title":"Overview on population screening for carriers with germline BRCA mutation in China","volume":"12","author":"Lei","year":"2022","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.20813\/ref-26","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00432-020-03377-6","article-title":"Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario","volume":"147","author":"Lerner-Ellis","year":"2021","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"key":"10.7717\/peerj.20813\/ref-27","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12967-024-05200-z","article-title":"In silico analysis of the wild-type and mutant-type of BRCA2 gene","volume":"22","author":"Li","year":"2024","journal-title":"Journal of Translational Medicine"},{"key":"10.7717\/peerj.20813\/ref-28","doi-asserted-by":"publisher","first-page":"6505","DOI":"10.2147\/cmar.S186563","article-title":"Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast\/ovarian cancer: a report from North India","volume":"10","author":"Mehta","year":"2018","journal-title":"Cancer Manag Res"},{"key":"10.7717\/peerj.20813\/ref-29","doi-asserted-by":"publisher","first-page":"1477980","DOI":"10.3389\/fimmu.2024.1477980","article-title":"Integrating immunotherapy with conventional treatment regime for breast cancer patients\u2014an amalgamation of armamentarium","volume":"15","author":"Nandi","year":"2024","journal-title":"Frontiers in Immunology"},{"issue":"21","key":"10.7717\/peerj.20813\/ref-30","doi-asserted-by":"publisher","first-page":"3458","DOI":"10.3390\/cells11213458","article-title":"Breast cancer cells reprogram the oncogenic lncRNAs\/mRNAs coexpression networks in three-dimensional microenvironment","volume":"11","author":"Nu\u00f1ez Olvera","year":"2022","journal-title":"Cell"},{"key":"10.7717\/peerj.20813\/ref-31","doi-asserted-by":"publisher","first-page":"6704","DOI":"10.1038\/s41598-022-10519-y","article-title":"Genetic, clinic and histopathologic characterization of BRCA-associated hereditary breast and ovarian cancer in southwestern Finland","volume":"12","author":"Pallonen","year":"2022","journal-title":"Scientific Reports"},{"key":"10.7717\/peerj.20813\/ref-32","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.4143\/crt.2021.978","article-title":"Implication and influence of multigene panel testing with genetic counseling in Korean patients with BRCA1\/2 mutation-negative breast cancer","volume":"54","author":"Park","year":"2022","journal-title":"Cancer Research and Treatment"},{"key":"10.7717\/peerj.20813\/ref-33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/GIM.0b013e31816b5cae","article-title":"ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007","volume":"10","author":"Richards","year":"2008","journal-title":"Genetics in Medicine"},{"key":"10.7717\/peerj.20813\/ref-34","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/grf.0000000000000239","article-title":"Breast Cancer Epidemiology and Risk Factors","volume":"59","author":"Rojas","year":"2016","journal-title":"Clinical Obstetrics and Gynecology"},{"key":"10.7717\/peerj.20813\/ref-35","doi-asserted-by":"publisher","first-page":"11782234221107580","DOI":"10.1177\/11782234221107580","article-title":"Evolving evidence for the optimization of neoadjuvant therapy in triple-negative breast cancer","volume":"16","author":"Silva","year":"2022","journal-title":"Breast Cancer"},{"key":"10.7717\/peerj.20813\/ref-36","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.3390\/curroncol31090362","article-title":"Estrogen Regulated Genes Compel Apoptosis in Breast Cancer Cells, Whilst Stimulate Antitumor Activity in Peritumoral Immune Cells in a Janus-Faced Manner","volume":"31","author":"Suba","year":"2024","journal-title":"Current Oncology"},{"key":"10.7717\/peerj.20813\/ref-37","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: gLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10.7717\/peerj.20813\/ref-38","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1007\/s12282-024-01603-4","article-title":"Neoadjuvant talazoparib in patients with germline BRCA1\/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status","volume":"31","author":"Telli","year":"2024","journal-title":"Breast Cancer"},{"key":"10.7717\/peerj.20813\/ref-39","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.20813\/ref-40","doi-asserted-by":"publisher","first-page":"e1867","DOI":"10.1002\/mgg3.1867","article-title":"Evaluation of the indication of BRCA1\/2 genetic tests in Iranian women and acceptance rate of risk-reducing surgeries in BRCA mutation carriers","volume":"10","author":"Vasigh","year":"2022","journal-title":"Molecular Genetics & Genomic Medicine"},{"key":"10.7717\/peerj.20813\/ref-41","doi-asserted-by":"publisher","first-page":"pkz095","DOI":"10.1093\/jncics\/pkz095","article-title":"Germline Testing for Patients With BRCA1\/2 Mutations on Somatic Tumor Testing","volume":"4","author":"Vlessis","year":"2020","journal-title":"JNCI Cancer Spectrum"},{"issue":"Suppl 1","key":"10.7717\/peerj.20813\/ref-42","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/ejhg.2016.94","article-title":"New challenges for BRCA testing: a view from the diagnostic laboratory","volume":"24","author":"Wallace","year":"2016","journal-title":"European Journal of Human Genetics"},{"key":"10.7717\/peerj.20813\/ref-43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clbc.2021.12.007","article-title":"Olaparib use in patients with metastatic breast cancer harboring somatic BRCA1\/2 mutations or mutations in non-BRCA1\/2, DNA damage repair genes","volume":"22","author":"Walsh","year":"2022","journal-title":"Clinical Breast Cancer"},{"key":"10.7717\/peerj.20813\/ref-44","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1093\/annonc\/mdw209","article-title":"Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic","volume":"27","author":"Winter","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.7717\/peerj.20813\/ref-45","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","article-title":"Human Epidermal Growth Factor Receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.20813\/ref-46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/1471-2164-15-244","article-title":"Comparison of somatic mutation calling methods in amplicon and whole exome sequence data","volume":"15","author":"Xu","year":"2014","journal-title":"BMC Genomics"},{"key":"10.7717\/peerj.20813\/ref-47","doi-asserted-by":"publisher","first-page":"4534","DOI":"10.21037\/tcr-24-704","article-title":"BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer","volume":"13","author":"Zhou","year":"2024","journal-title":"Translational Cancer Research"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20813.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20813.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20813.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20813.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:20:30Z","timestamp":1772526030000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":47,"alternative-id":["10.7717\/peerj.20813"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20813","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"e20813"}}